Provided by Tiger Trade Technology Pte. Ltd.

iBio

1.36
-0.0400-2.86%
Post-market: 1.390.0291+2.14%19:30 EDT
Volume:521.25K
Turnover:712.14K
Market Cap:67.56M
PE:-2.43
High:1.42
Open:1.42
Low:1.34
Close:1.40
52wk High:3.82
52wk Low:0.7708
Shares:49.68M
Float Shares:34.88M
Volume Ratio:1.11
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5600
EPS(LYR):-1.7504
ROE:-65.70%
ROA:-30.80%
PB:0.79
PE(LYR):-0.78

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 29

iBio Advances IBIO-600 into Phase 1 Multiple-Ascending-Dose Trial Stage After Completing Single-Ascending-Dose Dosing

Reuters
·
Aug 28

iBio FY26 Net Loss Widens to $33.04 Million; Revenue Drops to $100,000

Reuters
·
Aug 28

Ibio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 28

Press Release: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 28

iBio Announces 2026 Annual Shareholder Meeting

Reuters
·
Aug 20

iBio appoints Molly Carr as chief medical officer

TIPRANKS
·
Aug 04

iBio Files Form 3 for Chief Medical Officer Molly Carr

Reuters
·
Aug 04

iBio Names Endocrinologist Molly Carr as Chief Medical Officer

Reuters
·
Aug 04

Ibio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

THOMSON REUTERS
·
Aug 04

iBio Updates Governance Deadlines for 2026 Annual Meeting

TIPRANKS
·
Jul 18

Ibio is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 02

Buy Rating Reiterated on iBio as IBIO-610 Data Underscore Differentiated Efficacy; $5 Price Target Maintained

TIPRANKS
·
Jul 02

iBio Highlights Promising New Preclinical Obesity Antibody Data

TIPRANKS
·
Jul 01

Ibio Reports Single Dose of Ibio-610 Achieved Near-complete Active Activin E Inhibition Through Eight Weeks in Obese Nhp Study

THOMSON REUTERS
·
Jul 01

Ibio Says Single-dose Ibio-610 Cuts Active Activin E 98% Through Eight Weeks in Obese Primate Study

Reuters
·
Jul 01

Savara COO Robert Lutz to take CFO role as Lowrance steps down for health reasons

Reuters
·
Jun 09

iBio Initiated at Outperform by Raymond James

Dow Jones
·
Jun 09

Raymond James Initiates iBio at Outperform With $5 Price Target

MT Newswires Live
·
Jun 08

iBio initiated with an Outperform at Raymond James

TIPRANKS
·
Jun 08